Business Wire

IL-PATHWAYS-DAIRY-ZERO

22.9.2021 09:02:06 CEST | Business Wire | Press release

Share
Forty Leading Organizations, Including 11 of the 20 Largest Dairy Companies in the World, Among First to Support New Global “Pathways to Dairy Net Zero” Climate Initiative

Pathways to Dairy Net Zero, a ground-breaking new climate initiative, is launching today during Climate Week and just prior to the United Nations (UN) Food Systems Summit. Forty leading organizations, including 11 of the 20 largest dairy companies in the world, have already declared their support for the effort. Collectively, these supporters represent approximately 30 percent of total milk production worldwide.

The new climate initiative demonstrates the global dairy sector’s commitment to reducing GHG emissions while continuing to produce nutritious foods for six billion people and provide for the livelihoods of one billion people.

“Pathways to Dairy Net Zero will accelerate climate efforts already underway and drive further necessary action to reduce dairy’s emissions over the next decades. The dairy sector has a lot to offer to lead this transition,” said Hein Schumacher, Chief Executive Officer of Royal FrieslandCampina and Chairman of Global Dairy Platform.

“Mengniu is proud to join the global dairy sector in uniting behind this effort, the first of its kind in agriculture, because we must all do our part to meet this worldwide climate challenge,” said Minfang (Jeffrey) Lu, Chief Executive Officer and Executive Director of China Mengniu Dairy Company.

The initiative is underpinned by six key principles:

  1. Mitigation. Continuing to improve production and process efficiency to further reduce the GHG emissions intensity of milk and dairy products.
  2. Greenhouse gas removals. Enhancing production practices that protect carbon sinks (soil, forests, grass, peatlands) and complement natural ecosystems.
  3. Avoidance and adaptation. Improving practices such as feed, manure, fertilizer and energy management.
  4. Insets and offsets. Identify and implement alternative, credible reduction options.
  5. Measurement and monitoring. Measuring greenhouse gas emissions to plan mitigation and monitor progress.
  6. Overall support. Promoting the global initiative and emphasizing the dairy sector’s climate ambition.

Identifying and Clarifying Plausible Mitigation Options

A multi-stakeholder group of organizations, including the global dairy sector and representatives from the scientific and research communities, are working together to develop science-based methodologies, tools and pathways that work for every dairy system.

Research is underway to identify where positive climate change action is possible. The study is led by Scotland’s Rural College and the New Zealand Agricultural Greenhouse Gas Research Centre, research institutions from two of the Global Research Alliance on Agricultural Greenhouse Gases’ 65 member countries, backed up by data and analysis from the UN Food and Agriculture Organization.

Initial research found that the dairy sector already has the means to reduce a significant proportion of emissions - up to 40 percent in some systems - by improving productivity and resource use efficiency.1

Researchers are identifying plausible GHG mitigation pathways for different dairy systems globally, in particular methane reduction. The latest Intergovernmental Panel on Climate Change (IPCC) report2 reaffirmed that the main GHG challenge is the reduction of carbon dioxide, which remains in the atmosphere for centuries. The report also identified reductions in methane, a potent but short-lived climate pollutant that lasts only about 12 years in the atmosphere, as an immediate opportunity to address global warming.

Organizations Already Supporting Pathways to Dairy Net Zero

The list so far includes: Nestle, Dairy Farmers of America, Danone, Fonterra Co-operative Group, Royal FrieslandCampina, Arla Foods, China Mengniu Dairy Company, Saputo, Meiji Holdings, Savencia Fromage & Dairy, Agropur Dairy Cooperative, Ace Farming Company, Agri Networking Tools, Australian Dairy Products Federation, Brazzale, Dairy Australia, Dairy Connect, Dairy Farmers of Canada, Dairy Management Inc., Dairy UK, Dutch Dairy Association, First Milk, FOSS Analytics, Glanbia, Granja Tepeyac, Innovation Center for U.S. Dairy, International Dairy Foods Association, La Vida Lactea, Land O’Lakes, Lekhanath Dairy International, Leprino Foods Company, Livestock Improvement Corporation, Megmilk Snow Brand, Morinaga Milk Industry, National Dairy Development Board (India), National Milk Producers Federation (U.S.), Palmhouse Dairies, Pioneer Natural Capital, Royal DSM, U.S. Dairy Export Council.

For more information, or to join Pathways to Dairy Net Zero, visit: www.pathwaystodairynetzero.org .

About Pathways to Dairy Net Zero

Pathways to Dairy Net Zero is a vibrant, growing movement, the first of its kind in the world. It brings together dairy systems of every size and type, including organizations throughout the dairy supply chain.

Partners include: Global Dairy Platform, International Dairy Federation, Sustainable Agriculture Initiative Platform, International Livestock Research Institute, Dairy Sustainability Framework and IFCN Dairy Research Network.

The Global Research Alliance on Agricultural Greenhouse Gases is a knowledge partner.

References

  1. Gerber PJ, Steinfeld H, Henderson B, et al. 2013. Tackling climate change through livestock – A global assessment of emissions and mitigation opportunities. Food and Agriculture Organization of the United Nations (FAO), Rome. Available at: http://www.fao.org/3/i3437e/i3437e.pdf [Accessed July 2021].
  2. IPCC, 2021: Climate Change 2021: The Physical Science Basis. Contribution of Working Group I to the Sixth Assessment Report of the Intergovernmental Panel on Climate Change [Masson-Delmotte, V., P. Zhai, A. Pirani, S. L. Connors, C. Péan, S. Berger, N. Caud, Y. Chen, L. Goldfarb, M. I. Gomis, M. Huang, K. Leitzell, E. Lonnoy, J. B. R. Matthews, T. K. Maycock, T. Waterfield, O. Yelekçi, R. Yu and B. Zhou (eds.)]. Cambridge University Press. In Press.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye